1. Home
  2. FFA vs ALT Comparison

FFA vs ALT Comparison

Compare FFA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FFA
  • ALT
  • Stock Information
  • Founded
  • FFA 2004
  • ALT 1997
  • Country
  • FFA United States
  • ALT United States
  • Employees
  • FFA N/A
  • ALT N/A
  • Industry
  • FFA Investment Managers
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • FFA Finance
  • ALT Health Care
  • Exchange
  • FFA Nasdaq
  • ALT Nasdaq
  • Market Cap
  • FFA 400.0M
  • ALT 472.3M
  • IPO Year
  • FFA N/A
  • ALT N/A
  • Fundamental
  • Price
  • FFA $18.11
  • ALT $4.55
  • Analyst Decision
  • FFA
  • ALT Strong Buy
  • Analyst Count
  • FFA 0
  • ALT 8
  • Target Price
  • FFA N/A
  • ALT $21.00
  • AVG Volume (30 Days)
  • FFA 26.1K
  • ALT 2.2M
  • Earning Date
  • FFA 01-01-0001
  • ALT 05-08-2025
  • Dividend Yield
  • FFA 6.72%
  • ALT N/A
  • EPS Growth
  • FFA N/A
  • ALT N/A
  • EPS
  • FFA N/A
  • ALT N/A
  • Revenue
  • FFA N/A
  • ALT $20,000.00
  • Revenue This Year
  • FFA N/A
  • ALT N/A
  • Revenue Next Year
  • FFA N/A
  • ALT N/A
  • P/E Ratio
  • FFA N/A
  • ALT N/A
  • Revenue Growth
  • FFA N/A
  • ALT N/A
  • 52 Week Low
  • FFA $15.84
  • ALT $3.55
  • 52 Week High
  • FFA $19.30
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • FFA 42.25
  • ALT 43.21
  • Support Level
  • FFA $17.84
  • ALT $4.32
  • Resistance Level
  • FFA $18.48
  • ALT $4.75
  • Average True Range (ATR)
  • FFA 0.68
  • ALT 0.38
  • MACD
  • FFA 0.04
  • ALT 0.05
  • Stochastic Oscillator
  • FFA 68.05
  • ALT 63.22

About FFA First Trust Enhanced Equity Income Fund

First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: